Statement of Principles concerning malignant neoplasm of the ovary (Balance of Probabilities) (No. 10 of 2018)

The central legal and medical concepts in the SOP are: the defined disease, the balance of probabilities causal standard, enumerated causal factors, temporal and exposure thresholds, the relationship-to-service requirement, cross-application with other SOPs, and dictionary definitions that operationalise clinical descriptors.

Defined disease and coding

• The SOP concerns primary malignant neoplasm of the ovary, meaning a primary tumour arising from ovarian cells (s 7(2)(a)). It expressly includes cell types of borderline malignant potential and expressly excludes soft tissue sarcoma, carcinoid tumour, non‑Hodgkin’s lymphoma and Hodgkin’s lymphoma (s 7(2)(b)-(c)). While it notes that ovarian malignant neoplasm attracts ICD‑10‑AM code C56 or D39.1, the substantive meaning for the SOP is the statutory definition in s 7(2) (s 7(3)-(4)).

Causal standard

• The SOP is framed around the civil standard, balance of probabilities, for causal connection. Section 8 states the Repatriation Medical Authority’s view that, on the sound medical‑scientific evidence available, it is more probable than not that malignant neoplasm of the ovary and death from it can be related to relevant service. Section 9 then identifies specific factual factors that must exist for a finding of connection.

Enumerated factors and threshold conditions

• Section 9 lists nine discrete factors any one of which, if established and related to relevant service, suffices to meet the SOP’s conditional requirement. Those factors are concrete and prescriptive: e.g. five-year duration of endometriosis before clinical onset (s 9(1)); cumulative ovarian ionising radiation dose of at least 0.5 sievert with at least a ten-year latency (s 9(2)); obesity (BMI ≥ 30) for at least five years within the 20 years preceding clinical onset (s 9(3)); specific asbestos inhalation thresholds measured in cumulative hours and differentiated by enclosed space (2 000 hours) versus open environment (6 000 hours) together with activity descriptors and a minimum ten‑year latency (s 9(4)-(5)); breastfeeding inability of cumulative six months for parous women (s 9(6)); parity and hormone replacement therapy requirements for epithelial ovarian cancer (s 9(7)); tobacco pack‑year thresholds for mucinous tumours with latency and cessation windows (s 9(8)); and inability to obtain appropriate clinical management (s 9(9)).

Temporal and exposure specifics

• Several factors impose precise temporal requirements (for example, latencies of at least ten years for radiation and asbestos exposures, smoking commencement at least ten years before onset for mucinous tumours) and exposure quantification (e.g. cumulative equivalent dose definition in the Schedule, pack‑year conversion measures, cumulative hours for asbestos). These operational elements are framed in the body of the SOP and tightened by the Schedule’s definitions.

Relationship to service

• The SOP does not simply list risk factors. Section 10 requires the existence of the factor to be related to the person’s relevant service. Section 10(2) qualifies the operation of s 9(9) to cases where the person suffered the ovarian neoplasm before or during (but not arising out of) relevant service; in those cases inability to obtain appropriate clinical management can only support a finding of material contribution or aggravation.

Cross-reference to other SOPs and external technical guides

• Section 11 provides that if a factor in s 9 refers to an injury or disease for which another SOP exists, then the factors in that other SOP apply in accordance with its terms. The Schedule also ties cumulative equivalent dose to a specific ARPANSA methodological guide as in force on 2 August 2017 and ties ICD coding to the Tenth Edition ICD‑10‑AM effective 1 July 2017.

Death definition

• Death from malignant neoplasm of the ovary includes death from a terminal event or condition contributed to by the ovarian neoplasm, and the Schedule defines ‘terminal event’ by reference to proximate causes such as pneumonia, respiratory failure, cardiac arrest and cessation of brain function (s 7(5); Schedule).

Collectively, the SOP converts epidemiological and clinical associations into discrete evidential triggers that a decision-maker may use when assessing whether an ovarian malignancy is service-related for veterans’ entitlements purposes. The Schedule’s definitions are integral because they operationalise BMI calculation, radiation dose computation, parity thresholds, tobacco exposure, and what counts as relevant service.

This SOP affects three overlapping groups, and it affects the administrative actors who apply the SOP in the veterans' entitlements system.

Veterans, members of the Forces, and their dependants

• The immediate substantive effect is on persons claiming benefits under the VEA or MRCA where a claim involves malignant neoplasm of the ovary or death from that disease (s 5). The SOP applies to claims to which s 120B of the VEA or s 339 of the MRCA applies (s 5). Those provisions in the underlying Acts set out the statutory mechanisms for establishing service connection; the SOP informs the medical causation element of those processes.

• Women (or persons with ovaries) who have been diagnosed with primary ovarian cancer, and their estates where death is involved, are the group whose ability to secure an entitlement finding is directly affected. The SOP’s inclusion of cell types of borderline malignant potential (s 7(2)(b)) expands the set of tumours that can be considered; the explicit exclusions in s 7(2)(c) narrow it by removing certain tumour types.

Decision-makers and medical assessors

• The Repatriation Medical Authority authored the SOP (s 3) and supplies the medical framework. Administering agencies and decision-makers under the VEA and MRCA must apply this SOP when deciding claims covered by the specified statutory provisions. The SOP defines evidentiary and temporal thresholds that assessors and medical officers will need to test against claimants’ records.

Healthcare providers and records custodians

• Clinicians, hospitals and diagnostic laboratories will be routinely tasked with producing the clinical records and pathology reports needed to establish tumour type, dates of clinical onset, treatment histories (including hormone replacement therapy), endometriosis diagnosis and duration, breastfeeding history, smoking consumption and cessation dates, BMI history, radiation exposure records and asbestos exposure corroboration. The Schedule’s definitions (for example BMI formula; pack‑year equivalence) mean that quantified clinical data will be required in many cases.

Employers and service record holders

• For exposures that require workplace or service corroboration,particularly asbestos exposure and ionising radiation,employers, unit commanders, or Defence/Service record custodians may be required to provide service histories, duty descriptions, location and activity evidence, radiation monitoring reports and other exposure documentation. The cumulative-hour and enclosed/open‑environment distinctions for asbestos will focus attention on where and how work was performed.

Who decides and who pays

• The SOP itself does not decide claims or pay benefits; it determines medical factors relevant to decisions. The administering departments and tribunals that process VEA/MRCA claims will be the decision-makers who apply this SOP when deciding entitlement. Any costs of obtaining evidence,histopathology, expert opinions (for example, on dose reconstruction or causal linkage), and obtaining service or employer records,are ordinarily borne by claimants unless specific support is available via veterans’ services. The SOP imposes evidential burdens on applicants who seek to invoke the enumerated factors as the basis for service connection.

Geographical and temporal scope

• The definitions of relevant service (Schedule) limit the SOP’s applicability to particular types of service: eligible war service other than operational service, defence service excluding hazardous service and British nuclear test defence service under the VEA, or peacetime service under the MRCA. Several factors also impose temporal limits , for example exposures must have occurred at least ten years prior for some factors (s 9(2), (4)(c), (5)(c), (8)(a)), and certain exposure/therapy cessation windows are specified (s 9(7)(b), (8)(b)).

In sum, the SOP affects claimant populations by prescribing specific, quantifiable medical and exposure criteria that must be met and related to a defined set of service types. It shifts evidentiary attention and costs onto demonstrating the presence, timing and service-relationship of those criteria.

This instrument is not normative in the sense of creating criminal offences, but it creates duties and rights within the veterans’ entitlements decision framework by setting out the factual and temporal preconditions for a finding of service connection for ovarian malignancy. The SOP frames what claimants must establish and what decision-makers must consider when applying the VEA and MRCA provisions referenced.

Claimant duties (evidential obligations)

• A claimant seeking to rely on a factor in s 9 must establish, on the balance of probabilities, that the factor existed and was related to the person’s relevant service. Section 10(1) states the factor must be related to the relevant service rendered by the person. This creates an evidentiary duty to adduce medical, service and other records that demonstrate both the factual existence of the factor (for example, five years of documented endometriosis, BMI records showing obesity for five years, prescription records for hormone replacement therapy for the required period) and a causal or service-related link.

• For exposure-based factors such as ionising radiation and asbestos, the claimant must adduce evidence to meet precise exposure thresholds: a cumulative equivalent dose of at least 0.5 sievert to the ovary (s 9(2)), or cumulative asbestos inhalation hours with activity descriptors and latency (s 9(4)-(5)). The Schedule defines the technical method for calculating cumulative equivalent dose and references a dated ARPANSA guide. Claimants will therefore need dose reconstruction evidence or monitoring data compliant with that methodology.

• For s 9(9) (inability to obtain appropriate clinical management), the claimant must also establish that the ovarian neoplasm was suffered or contracted before or during but did not arise out of relevant service when the factor is relied upon for material contribution or aggravation (s 10(2)). This introduces a particular evidentiary pathway for pre‑existing disease aggravated by service-related lack of access to care.

Decision-maker duties (application of SOP)

• Decision-makers under the VEA and MRCA, when dealing with claims to which the SOP applies (s 5), must apply the SOP as an authoritative statement of medical causation factors in determining whether, on the balance of probabilities, malignant neoplasm of the ovary is connected with service (s 8; s 9). Section 11 requires that where a factor in s 9 refers to an injury or disease covered by another SOP, the other SOP’s factors apply according to its terms. This imposes a duty on decision-makers to cross-check relevant SOPs and to apply their criteria consistently.

Rights of claimants

• The SOP operates to define a claimant’s entitlement pathway. If a claimant can establish one or more of the enumerated factors and relate it/them to relevant service in accordance with s 10, that forms a prima facie basis for a finding of service connection under the VEA s 120B or MRCA s 339 framework (by virtue of s 5). The SOP thereby creates a demonstrable route to entitlement; conversely, absence of any of the listed factors makes it harder to satisfy the SOP’s medical thresholds.

No penalties or prosecution rights created by the SOP

• The instrument does not create offences, fines or administrative penalties. It is diagnostic and evidential. Enforcement is through the administrative claims process under the VEA and MRCA rather than by criminal sanction.

Interaction with technical definitions and external documents

• The Schedule fixes significant technical definitions. For example, BMI is defined by the explicit formula W/H2 and obesity is BMI ≥ 30. The Schedule’s cumulative equivalent dose definition requires calculation according to a named ARPANSA guide as in force on 2 August 2017. These definitional choices impose duties on decision-makers to use those technical standards and impose corresponding evidentiary duties on claimants and expert witnesses.

Who decides contested factual questions

• The SOP supplies the criteria, but determination of whether factual thresholds are met remains within the decision-making process established by the VEA and MRCA. The instrument binds the interpretation of medical causation to the factors and definitions it contains; it does not itself adjudicate individual claims.

In short, the SOP establishes what claimants must prove and what medical and technical standards decision-makers must apply to determine whether ovarian cancer or death from it is connected with relevant service.

This Statement of Principles is a medical-technical instrument and does not create criminal offences, civil sanctions, or direct enforcement mechanisms by itself. It is not drafted as penal legislation; it neither prescribes penalties nor confers enforcement powers. Its enforcement function operates indirectly through administrative decision-making under the VEA and MRCA.

Administrative enforcement pathway

• The SOP is applied by decision-makers determining claims under s 120B of the VEA or s 339 of the MRCA (s 5). Where a claimant relies on the SOP’s factors to establish service connection for malignant neoplasm of the ovary or death from that disease, the administering agency will apply the SOP as part of the evidentiary and medical assessment. The ultimate administrative decision on entitlement will follow statutory processes and review mechanisms available under the VEA or MRCA and the general administrative law framework. The SOP itself does not change those statutory appeal or review pathways.

No fines or criminal liability in the instrument

• There are no penal provisions in the SOP text. It does not impose regulatory offences on employers, clinicians or any other person for failing to record exposures, nor does it create liability regimes or compensation obligations independent of the VEA/MRCA claim process. Any compensation or payment arises only through successful claims under the relevant Acts, applying the SOP as a medical causation tool.

Evidence and proof, not coercive powers

• The SOP sets evidential thresholds (for example, exposure quantities and temporal windows) but does not create investigatory powers. Where evidence is lacking, claimants may be required to produce expert reports, service records and medical documentation to prove the factors (e.g. dose reconstructions or smoking history). The instrument does not specify mechanisms for compelling production of such evidence; those mechanisms, if any, derive from the administrative and tribunal processes of the underlying Acts and general law (subpoenas, disclosure rules, record‑keeping obligations).

Revocation and temporal operation

• The SOP revokes the earlier SOP No. 71 of 2009 (s 4). Once in force, it governs medical causation questions for the classes of claims to which it applies from its commencement date (s 2). The endnotes record amendment history and dates which affect the instrument’s current text and operational scope (endnotes 3 and 4). Administrative actors must enforce the correct, current SOP; using an out-of-date SOP would misapply the medical criteria.

Implications for record-keeping and documentation

• Since the SOP relies on quantifiable exposures and durations (for example, cumulative equivalent radiation dose per the ARPANSA Guide, BMI values, pack‑year computations, cumulative asbestos hours with an enclosed/open environment distinction), its application will generate enforcement-like effects in practice: claimants and their advisers will need to procure technical evidence and expert opinion to satisfy the SOP’s thresholds. The SOP thereby creates practical evidentiary ‘obligations’ in the form of documentation and expert evidence, though not legal penalties for non-compliance with the SOP itself.

In summary, enforcement of the SOP is administrative and evidentiary rather than penal; the instrument prescribes thresholds and definitions that decision-makers must apply but does not itself carry punitive sanctions.

The SOP is an instrument made under the VEA and designed to interface with the VEA and MRCA claims regimes, with cross-references to other Statements of Principles, external taxonomies and a named technical guide.

Statutory basis and application

• The SOP is made under subsection 196B(3) of the VEA (s 3). It expressly applies to claims to which s 120B of the VEA or s 339 of the MRCA apply (s 5). Those provisions in the underlying statutes are the legal gateways through which the SOP has operative effect,i.e. the SOP is an evidentiary template for determining causation within those statutory claims frameworks.

Cross-application with other Statements of Principles

• Section 11 provides a mechanism for cross-application: if a factor in s 9 refers to an injury or disease for which another SOP exists (determined under s 196B(3) of the VEA), then the factors in that other SOP apply according to its terms. This creates an integrated SOP network where, for example, an asbestos exposure factor that refers to asbestosis or pleural disease would bring the other SOP’s criteria into play. Decision-makers must therefore identify relevant SOPs and apply them as a package where factors intersect across instruments.

References to external technical standards

• The Schedule links key technical definitions to external instruments and editions: cumulative equivalent dose is to be calculated in accordance with the methodology set out in the ARPANSA Guide as in force on 2 August 2017 (Schedule, cumulative equivalent dose definition). ICD‑10‑AM codes are referenced to the Tenth Edition, effective 1 July 2017 (s 7(4)). By fixing specific versions, the SOP operationally ties medical causation calculations to particular technical editions rather than to an open-ended, evolving standard. Decisions about dose reconstruction must therefore refer to the ARPANSA guide version specified.

Interaction with the VEA and MRCA decision process

• The SOP does not replace statutory tests in the VEA or MRCA. Rather, it supplies a medical-causation input for the statutory decision-maker. For instance, the VEA and MRCA set out the legal criteria and eligibility pathways, while the SOP prescribes the medical factors that, if present and related to relevant service, establish a link on the balance of probabilities. Decision-makers remain bound by the statutory provisions governing claims, admissible evidence, procedural fairness and review rights.

Definitions of relevant service

• The Schedule’s definition of relevant service interacts tightly with the VEA/MRCA statutory categories of service. The Schedule defines relevant service to mean (a) eligible war service other than operational service under the VEA, (b) defence service other than hazardous service and British nuclear test defence service under the VEA, or (c) peacetime service under the MRCA. This places limits on the types of service activities that can attract the SOP’s application and interact with the underlying statutory eligibility rules.

No interaction with criminal or occupational safety laws

• The SOP does not purport to displace or interact directly with criminal laws, occupational health and safety legislation, workers’ compensation schemes, or tort law. It is not a vehicle for asserting employer liability or regulatory breach outside the VEA/MRCA claims context. However, practical evidence developed under other regimes (for example, workplace exposure records, workers’ compensation findings, or occupational health monitoring reports) will be relevant and likely admissible in supporting or opposing a claim under the VEA/MRCA where the SOP applies.

Temporal and amendment interactions

• The SOP revokes a prior SOP (s 4) and has itself been amended (endnote entries). Administrators and practitioners must ensure they apply the then-current SOP. The Schedule’s fixed references to particular editions of technical guides and ICD‑10‑AM can affect interaction where those external documents are later updated; because the SOP fixes specified editions/dates, later versions of those external guides are not automatically incorporated unless the SOP is amended.

In short, the SOP is embedded in the VEA/MRCA statutory network, cross-links to other SOPs where factors refer to other diseases, and adopts external technical standards by reference. It interacts with, but does not supplant, the statutory claims processes and other bodies of law outside veterans’ entitlements.

The text includes its own compilation notes and endnotes that record its creation, amendment and commencement dates.

Original instrument and commencement

• The instrument is registered as Statement of Principles concerning malignant neoplasm of the ovary No. 10 of 2018 (Endnote 3). It was registered 2 January 2018 (F2018L00011) and commenced on 29 January 2018 (s 2 and endnote 3).

Revocation of prior SOP

• Section 4 states that this instrument revokes the Statement of Principles concerning malignant neoplasm of the ovary No. 71 of 2009, as amended, which had been made under subsections 196B(3) and (8) of the VEA. That indicates a full replacement rather than a supplemental amendment of the earlier SOP.

Subsequent amendment (Instrument No. 36 of 2018)

• The compilation includes Amendment Statement of Principles concerning malignant neoplasm of the ovary No. 36 of 2018 (F2018L00184). That amendment instrument was registered 5 March 2018 and commenced on 2 April 2018 (Endnote 3). The compilation notes that the day of commencement of this amendment SOP is 2 April 2018.

Provision-level amendment history

• Endnote 4 records that subsection 10(2) was re-substituted/affected by Instrument No. 36 of 2018 (listed as "Subsection 10(2)... rs Instrument No. 36 of 2018"). The endnote implies targeted textual changes to subsection 10(2) occurred as part of that amendment.

Compilation date and scope

• The compilation presents the SOP as amended and in force on 2 April 2018 (Compilation No. 1, compilation date 2 April 2018). The front material instructs users that uncommenced amendments are not shown and that modifications by other laws may operate without amending the text in the compilation.

References fixed by date

• The Schedule ties external references to specific versions and dates (e.g. ARPANSA guide as in force on 2 August 2017; ICD‑10‑AM Tenth Edition effective 1 July 2017). These fixed-date references mean that unless the SOP is amended, subsequent revisions of those external documents do not automatically change how the SOP is applied.

Endnote administrative material

• The compilation includes standard endnotes explaining the abbreviation key, legislation history and amendment history (Endnotes 1-4). Those endnotes provide the formal record of registration and commencement dates listed above.

Practical effect of amendments

• The textual change to subsection 10(2) via Instrument No. 36 of 2018 is the only provision-level amendment recorded in the endnotes. Given subsection 10(2) governs the operation of factor 9(9) (inability to obtain appropriate clinical management) and its application to material contribution or aggravation in cases where the disease was suffered or contracted before or during service (but did not arise out of service), this amendment potentially affects the evidential pathway and scope for cases relying on s 9(9).

Record of prior law

• The instrument’s revocation of SOP No. 71 of 2009 means practitioners should check archived versions where claims or facts predate the replacement, or where transitional provisions in the decision framework might refer to earlier SOPs. The compilation explicitly states that application, saving and transitional provisions not included in the compilation are recorded in the endnotes (front matter).

Overall, the amendment history recorded in the compilation is concise: instrument made late 2017/early 2018, commenced 29 January 2018, amended by Instrument No. 36 registered 5 March 2018 and commencing 2 April 2018, with a specific change to subsection 10(2).

The compilation of the SOP does not record any litigation, court decisions, tribunal determinations, or judicial interpretation of this specific Statement of Principles. The text contains no citations to cases nor references to legal proceedings that have tested or interpreted the SOP. The only judicial or adjudicative context provided is administrative: the SOP is intended for use within the claims decision-making framework established by the VEA and the MRCA (s 5).

Consequences for practitioners

• Because no litigation history is recorded in the instrument, practitioners will not find authority in this compilation for judicial interpretation or challenge points specific to this SOP. Any case law that may later arise interpreting the SOP’s definitions, the weight to be given to particular factors, or the proper method for applying the ARPANSA cumulative dose guide will need to be located in external case law databases or tribunal decisions. The SOP itself does not include such material.

Potential areas where litigation might arise (based on the SOP’s contents)

• Although the compilation does not supply litigation history, the SOP’s technical thresholds and cross-references suggest possible future dispute areas:
  • Interpretation of the Schedule’s technical definitions (for example, the method for calculating cumulative equivalent dose per the ARPANSA guide, BMI measurement periods, pack‑year calculations).
  • Application and sufficiency of evidence to prove exposure thresholds (e.g. sufficiency of contemporaneous service records versus reconstructed estimates).
  • The legal effect of s 10(2)’s limitation on s 9(9) (inability to obtain appropriate clinical management) and what constitutes adequate evidence of inability to obtain appropriate management.
  • Cross‑application and priority between this SOP and other SOPs where s 11 brings them into play.

No recorded appeals or judicial review material

• The compilation does not list any tribunal appeals or judicial review decisions that reference this SOP. Practitioners should therefore check veterans’ appeal tribunal records, AAT decisions and court databases for any subsequent determinations that might have interpreted or tested the SOP after the compilation date.

In short, the SOP as compiled contains no litigation history. Any analysis of how courts or tribunals have applied it must rely on external research beyond the compilation.

This SOP contains a number of technical, temporal and definitional features that can produce practical pitfalls for claimants, advisers and decision-makers. The following are source‑grounded points of caution.

Fixed external references and methodology dates

• The cumulative equivalent dose definition requires calculation "in accordance with the methodology set out in" the ARPANSA Guide, "as in force on 2 August 2017" (Schedule). That fixes the applicable dose‑reconstruction methodology to a particular version. Practitioners should not assume later ARPANSA revisions apply; evidence and expert reports must be prepared against the guide version specified in the SOP.

• Similarly, the ICD‑10‑AM reference is to the Tenth Edition, effective 1 July 2017 (s 7(4)). The SOP also states its own definition (s 7(2)) overrides reliance on ICD codes for substantive meaning. Nonetheless, these date‑specific references are important when assembling coding-based documentation.

Strict temporal and exposure thresholds

• Many factors have hard thresholds and latency windows. Examples include:
  • Radiation: cumulative equivalent dose of at least 0.5 sievert to the ovary, with first exposure at least ten years before clinical onset (s 9(2)).
  • Asbestos: enclosed environment cumulative period of at least 2 000 hours, open environment at least 6 000 hours, first inhalation at least ten years before clinical onset, and activity-specific exposure circumstances (s 9(4)-(5)).
  • Obesity: being obese (BMI ≥ 30) for at least five years within the 20 years before clinical onset (s 9(3)).
  • HRT: at least five consecutive years before clinical onset and, if ceased, clinical onset within ten years after that period for epithelial ovarian cancer (s 9(7)(b)).
  • Smoking for mucinous tumours: at least ten pack‑years, smoking must have commenced at least ten years before clinical onset, and if ceased, clinical onset within 20 years of cessation (s 9(8)). These thresholds mean partial or borderline exposures may fail to meet the SOP even if the exposure is clinically relevant in another context.

Disease type specificity

• Several factors apply only to certain histological subsets. For example:
  • s 9(6) applies only to parous women.
  • s 9(7) applies only to epithelial ovarian cancer (nulliparity and HRT criteria).
  • s 9(8) applies only to mucinous ovarian tumours (smoking). Therefore, pathology and histological confirmation are critical; misclassification can negate reliance on a factor.

Definitions that change evidential strategy

• The SOP’s Schedule defines pack‑years with a specific equivalence (one pack‑year = 20 tailor‑made cigarettes/day for one year, equals 7 300 cigarettes; one tailor‑made cigarette approximates one gram of tobacco; one pack‑year equates to 7.3 kg of smoking tobacco) and includes equivalence to pipe or cigar tobacco by weight. This level of quantification requires detailed smoking histories and, where necessary, conversion calculations that align with the Schedule’s formula.

• Being obese is defined strictly by BMI formula (W/H2) and a threshold (BMI ≥ 30). Claimants must provide weight/height records over time to show sustained obesity for the required period.

s 9(9) and s 10(2) interplay

• The inability to obtain appropriate clinical management (s 9(9)) is constrained by s 10(2): it only applies to material contribution or aggravation where the ovarian neoplasm was suffered or contracted before or during (but did not arise out of) the person's relevant service. This requires careful sequencing: the disease must pre-date or be concurrent with service and yet not have arisen out of service. Demonstrating that inability to obtain appropriate management was causally material or aggravating will require contemporaneous evidence of care access issues and expert medical opinion linking lack of management to worsening.

Relevant service limitations

• The Schedule definition of relevant service excludes hazardous service and British nuclear test defence service under the VEA, and it distinguishes between eligible war, defence and peacetime service categories. That narrowing may exclude certain exposures from being capable of satisfying the SOP unless they fall squarely within the defined relevant service types.

Exclusions within malignant neoplasm definition

• The SOP excludes certain tumour types (soft tissue sarcoma, carcinoid tumour, non‑Hodgkin's lymphoma and Hodgkin's lymphoma) from the meaning of malignant neoplasm of the ovary for this SOP (s 7(2)(c)). Practitioners must ensure histopathology supports a tumour type covered by the SOP.

Evidence quality and burden

• The SOP’s quantitative thresholds increase the importance of expert evidence, dose reconstructions, service and employment records, and accurate medical histories. Weak or unquantified evidence of exposure or duration may not cross the thresholds and may result in a negative finding even where clinical plausibility exists.

No penalties but practical burdens

• Although the SOP imposes no penalties, the practical burden of proving the factors (gathering long‑term BMI data, establishing cumulative asbestos hours, reconstructing an ovarian radiation dose) can be substantial and costly for claimants. There is no text in the SOP providing for state-funded assessments; costs of obtaining required evidence will typically fall on the claimant unless support exists elsewhere in the VEA/MRCA framework.

Cross-SOP complexity

• Where s 11 imports criteria from other SOPs, practitioners must identify and reconcile multiple SOPs. This can introduce complexity if the other SOPs have different thresholds, definitions or technical guides.

In short, the SOP’s precise thresholds, definitional choices, temporal limits and cross-references create numerous evidential and procedural traps that require careful attention to the instrument’s text and the Schedule’s definitions.

Complying with the SOP for the purpose of pursuing a VEA s 120B or MRCA s 339 claim requires a targeted evidentiary and procedural strategy that addresses the SOP’s technical thresholds, temporal windows and relationship-to-service requirements. The following practical checklist and guidance are grounded in the SOP’s text and the Schedule definitions.

1. Confirm tumour type and clinical onset

• Obtain the full pathology and histology reports to confirm the diagnosis is a primary malignant neoplasm of the ovary as defined in s 7(2). Ensure documentation excludes the expressly excluded tumour types (soft tissue sarcoma, carcinoid tumour, non‑Hodgkin's lymphoma, Hodgkin's lymphoma) and identifies whether the tumour is epithelial, mucinous, germ cell, stromal, or borderline malignant potential, because eligibility to rely on particular factors in s 9 can be histology-specific (s 7(2)(b)-(c); s 9(7)-(8)).

• Identify the clinical onset date (the SOP refers to "clinical onset"), and collate contemporaneous medical records, diagnostic imaging, histopathology dates and clinical notes that establish the date or narrow the onset window (s 9 temporal references).

2. Map potential qualifying factors from s 9

• Systematically evaluate whether any of s 9(1)-(9) is likely to be present:
  • Endometriosis for at least five years before clinical onset (s 9(1)): compile gynaecological records, operative notes, diagnosis dates and specialist letters documenting chronicity.
  • Radiation exposure totalling ≥0.5 sievert to the ovary with latency ≥10 years (s 9(2)): gather all relevant radiation records, diagnostic/therapeutic imaging histories, aircrew service records, and any monitoring reports.
  • Obesity (BMI ≥30) for at least five years within the 20 years before onset (s 9(3)): compile serial weight and height records, primary care notes, clinic charts, hospital admissions and any occupational medicals to calculate BMI over time using Schedule BMI formula W/H2.
  • Asbestos exposure thresholds (s 9(4)-(5)): collect employment records, duty statements, service logs, witness statements and workplace exposure monitoring that demonstrate cumulative hours, nature of environment (enclosed v open), and activities (application, removal, dislodging, cutting, drilling).
  • Breastfeeding inability for parous women with cumulative six months before onset (s 9(6)): obtain obstetric notes and lactation records.
  • Nulliparity and HRT for epithelial ovarian cancer (s 9(7)): document full reproductive history (parity, gestations of at least 20 weeks as per 'nulliparous' definition) and prescription records for HRT establishing five consecutive years and timing of cessation relative to onset (HRT definition in Schedule).
  • Smoking for mucinous tumours (s 9(8)): obtain a detailed smoking history and convert to pack‑years per the Schedule's pack-year calculation (accounting for equivalences for pipe/cigar tobacco by weight).
  • Inability to obtain appropriate clinical management (s 9(9)): collate contemporaneous clinical notes, referral attempts, correspondence, facility logs, and evidence of access barriers. Remember s 10(2)'s limitation: s 9(9) applies to material contribution or aggravation when the disease was suffered or contracted before or during but not arising out of service.
• For each potential factor, assemble dates and corroborating support to meet the specific temporal and quantitative thresholds in the SOP.

3. Build technical and expert evidence

• For radiation dose: commission a dose reconstruction prepared in accordance with the ARPANSA Guide methodology as in force on 2 August 2017 (Schedule). Ensure the expert explicitly states compliance with the named guide and uses the ovarian tissue average dose calculation approach described in the Schedule.

• For asbestos exposure: obtain an occupational hygienist report that quantifies cumulative exposure hours, distinguishes enclosed versus open environments, and ties the activities to the SOP’s activity descriptors (application, removal, dislodging, cutting, drilling). Where monitoring is unavailable, seek reasoned exposure reconstruction that aligns to the SOP’s thresholds.

• For obesity and BMI history: instruct a clinician to prepare a chart of serial BMI calculations (W/H2) demonstrating BMI ≥30 for required durations, with signed documentation of sources for weight/height entries.

• For smoking: have an expert calculate pack‑years according to the Schedule’s formula (one pack = 20 tailor‑made cigarettes = 1 gram each; convert other products by weight where necessary) and document smoking commencement and cessation dates relative to clinical onset.

• For s 9(9) inability to obtain appropriate clinical management: assemble expert clinical opinion that links lack of management or delayed management to material contribution or aggravation of the ovarian cancer, and establish that the disease was suffered or contracted before/during service if relying on s 10(2).

4. Demonstrate relationship to relevant service

• For each factor relied upon, link the factor to the person’s relevant service (s 10(1)). Collect service records (unit postings, deployment dates, duty descriptions), employer records, Defence medical records, and contemporaneous logs that show the factor occurred in the course of relevant service as defined in the Schedule (eligible war service, defence service excluding hazardous/ British nuclear test defence service, peacetime service under MRCA).

• Be aware that relevant service excludes certain categories; verify the claimant’s service classification before relying on service-related exposure evidence.

5. Cross-check other SOPs

• Where a factor in s 9 refers to another disease/injury for which a SOP exists, consult that SOP (s 11). For example, if asbestos exposure is relied on but that exposure also relates to an asbestos‑related respiratory SOP, obtain and apply the other SOP’s factors as required. Ensure any cross-applied SOP is current and identify any potential conflicts or additional thresholds.

6. Prepare a coherent medical causation narrative

• Combine the factual evidence and expert opinions into a coherent causation statement that addresses:
  • The condition and histology (s 7(2));
  • The existence and timing of the claimed factor(s) against the SOP thresholds (s 9);
  • The causal link between the factor(s) and the ovarian neoplasm or death, on the balance of probabilities (s 8);
  • The relationship between the factor(s) and the person’s relevant service (s 10).

7. Anticipate evidentiary gaps and mitigation

• Where direct measures are unavailable (e.g. no contemporaneous asbestos monitoring), rely on alternative corroboration: contemporaneous duty lists, multiple witness statements, photographic or operations records, workplace safe‑work procedures that demonstrate likely exposure, and reasoned expert reconstructions consistent with the ARPANSA guide or occupational hygiene practice.

• For obesity claims, recognise that BMI snapshots may not show sustained periods; consider using GP records, medication records, hospital admissions and other objective sources to create a longitudinal BMI picture.

8. Procedural steps in the claims process

• Lodge the claim under the appropriate statutory route (VEA/MRCA) and ensure that the submission highlights the SOP factors being relied upon, attaches the technical expert reports, and references the Schedule definitions and ARPANSA guide compliance where relevant.

• Consider seeking an opinion from a RMA‑recognised medical specialist where available, and ensure that experts explicitly address SOP thresholds (for example, stating whether the ARPANSA‑method dose reconstruction yields ≥0.5 sievert to the ovary).

9. Keep versions and dates in view

• Confirm that all technical evidence is aligned to the SOP’s fixed references (ARPANSA guide as of 2 August 2017; ICD‑10‑AM Tenth Edition effective 1 July 2017). If experts use different methodologies or updated guides, require them to reconcile their method with the version specified in the SOP or explain why the alternative approach is valid for the SOP’s purposes.

10. Prepare for review and appeal

• Document chains of evidence and ensure expert reports explain reasoning and source material thoroughly to withstand administrative review and potential appeals. Because the SOP sets a balance-of-probabilities test tethered to discrete factors, appellate review will focus on whether factual thresholds and service relationships are established; clear, contemporaneous and quantified evidence is therefore essential.

This compliance approach organises the SOP’s textual requirements into practical evidentiary and procedural steps. The Schedule’s definitions and the SOP’s temporal and quantitative thresholds must be front and centre when assembling a claim or advising a client.